A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

Overview of attention for article published in Frontiers in immunology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2

Preprint in bioRxiv (June 2024)

SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?

Article in Antiviral Research (April 2024)

Next-generation treatments: Immunotherapy and advanced therapies for COVID-19

Article in Heliyon (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.